{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:17:20Z","timestamp":1780053440625,"version":"3.54.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Blood-based biomarkers including systemic inflammation (SI) indicators or circulating factors (cytokines, chemokines, or growth factors) are associated with a poor prognosis for lung cancer patients. Collectively these biomarkers can predict the immune state of a patient. We wanted to define and compare the immune states of small cell and non-small cell lung cancer patients, in the hopes that the information gained could lead to overall improvements in patient care and outcomes. Specimens and data from 235 patients was utilized, 49 surgically resected non-small cell lung cancer (NSCLC) patients with no evidence of disease (DF), 135 advanced non-small cell lung cancer (NSCLC), 51 small cell lung cancer (SCLC). SI markers neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR), systemic inflammation index (SII), and systemic inflammation response index (SIRI) were determined from blood counts. Forty-seven plasma cytokines were measured using a multiplex bead-based assay. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meier and Cox Proportional Hazards models. NSCLC patients had significantly high levels of SI markers than SCLC and DF patients, while NLR, PLR and SII were also higher in SCLC than DF patients. SI optimized marker values to differentiate SI value were; 6.04 (NLR), 320 (PLR), 1615 (SII), and 7.3 (SIRI). Elevated levels NLR (p&lt;0.001), PLR (p&lt;0.001), and SII (p = 0.018) were associated with a worse PFS and OS in NSCLC, while none of the markers were associated with PFS in SCLC patients. NSCLC patients with a poor outcome displayed heterogeneous immune states relative to systemic inflammation and circulating IL-6 markers. These groups could be distinguished based on the cytokines IL-8, TNF\u03b1, and IL-27. We identified heterogeneity of immune states in SCLC and NSCLC patients and in NSCLC patients with the poorest prognosis. This heterogeneity could be exploited to improve outcomes for these patients.<\/jats:p>","DOI":"10.1371\/journal.pone.0260988","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T19:38:53Z","timestamp":1638473933000},"page":"e0260988","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer"],"prefix":"10.1371","volume":"16","author":[{"given":"Shawn J.","family":"Rice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-5329","authenticated-orcid":true,"given":"Chandra P.","family":"Belani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"pone.0260988.ref001","unstructured":"Cancer.Net. Lung Cancer\u2014Non-Small Cell: Statistics: ASCO; 2020 [updated 5\/202012\/31\/20]. Available from: https:\/\/www.cancer.net\/cancer-types\/lung-cancer-non-small-cell\/statistics."},{"issue":"7","key":"pone.0260988.ref002","doi-asserted-by":"crossref","first-page":"272","DOI":"10.46883\/ONC.2020.3407.0272","article-title":"Immunotherapy in Advanced Lung Cancer","volume":"34","author":"J Huang","year":"2020","journal-title":"Oncology (Williston Park)."},{"issue":"2","key":"pone.0260988.ref003","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"J Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0260988.ref004","article-title":"KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum -based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programed cell death ligand 1 (PD_L1).","author":"J Brahmer","year":"2015","journal-title":"J. Clin. Oncol"},{"issue":"2","key":"pone.0260988.ref005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"FR Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"58","key":"pone.0260988.ref006","doi-asserted-by":"crossref","first-page":"98524","DOI":"10.18632\/oncotarget.21567","article-title":"PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study","volume":"8","author":"H Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"pone.0260988.ref007","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer","volume":"2","author":"J McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"pone.0260988.ref008","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fcell.2018.00056","article-title":"Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment","volume":"6","author":"EA Comen","year":"2018","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"pone.0260988.ref009","first-page":"6449","article-title":"The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer","volume":"14","author":"L Wang","year":"2017","journal-title":"Oncol Lett"},{"issue":"4","key":"pone.0260988.ref010","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2478\/raon-2020-0054","article-title":"Neutrophil-to-lymphocyte ratio can predict outcome in extensive-stage small cell lung cancer","volume":"54","author":"G Drpa","year":"2020","journal-title":"Radiol Oncol"},{"issue":"7","key":"pone.0260988.ref011","doi-asserted-by":"crossref","first-page":"e0219060","DOI":"10.1371\/journal.pone.0219060","article-title":"Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers","volume":"14","author":"M Dusselier","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"pone.0260988.ref012","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1186\/s12885-017-3893-1","article-title":"High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer","volume":"17","author":"D Liu","year":"2017","journal-title":"BMC Cancer"},{"issue":"4","key":"pone.0260988.ref013","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.21037\/jtd.2020.02.27","article-title":"The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab","volume":"12","author":"T Matsubara","year":"2020","journal-title":"J Thorac Dis"},{"issue":"4","key":"pone.0260988.ref014","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s10147-018-1250-2","article-title":"Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab","volume":"23","author":"A Nakaya","year":"2018","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"pone.0260988.ref015","first-page":"1417","article-title":"Prognostic Value of the Neutrophil to Lymphocyte Ratio (NLR) in Lung Cancer Cases","volume":"18","author":"B Ozyurek","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"pone.0260988.ref016","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.2147\/OTT.S199176","article-title":"Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB).","volume":"12","author":"F Ren","year":"2019","journal-title":"Onco Targets Ther"},{"key":"pone.0260988.ref017","first-page":"1178","author":"X Wang","journal-title":"Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer"},{"issue":"10","key":"pone.0260988.ref018","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/1759-7714.12838","article-title":"Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer","volume":"9","author":"T Takeda","year":"2018","journal-title":"Thorac Cancer"},{"issue":"8","key":"pone.0260988.ref019","doi-asserted-by":"crossref","first-page":"e22964","DOI":"10.1002\/jcla.22964","article-title":"Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab","volume":"33","author":"J Liu","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"pone.0260988.ref020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2019.03.014","article-title":"Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling","volume":"131","author":"SJ Rice","year":"2019","journal-title":"Lung Cancer"},{"issue":"7","key":"pone.0260988.ref021","doi-asserted-by":"crossref","first-page":"e0181125","DOI":"10.1371\/journal.pone.0181125","article-title":"High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer","volume":"12","author":"EM Silva","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"pone.0260988.ref022","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/ijc.27892","article-title":"Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy","volume":"132","author":"CH Chang","year":"2013","journal-title":"Int J Cancer"},{"issue":"12","key":"pone.0260988.ref023","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00432-017-2506-3","article-title":"Systemic Inflammation Response Index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection","volume":"143","author":"S Li","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"pone.0260988.ref024","doi-asserted-by":"crossref","first-page":"e13788","DOI":"10.1097\/MD.0000000000013788","article-title":"Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis","volume":"98","author":"Y Zhang","year":"2019","journal-title":"Medicine (Baltimore)."},{"key":"pone.0260988.ref025","unstructured":"CRAN. The Comprehensive R Archive Network 10\/10\/2020. Available from: https:\/\/cran.r-project.org\/."},{"issue":"4","key":"pone.0260988.ref026","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/JTO.0b013e3182037b76","article-title":"The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer","volume":"6","author":"RM Bremnes","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"11","key":"pone.0260988.ref027","doi-asserted-by":"crossref","first-page":"667","DOI":"10.21037\/atm.2020.03.174","article-title":"Systemic immune-inflammation index and prognosis of advanced non-small cell lung cancer","volume":"8","author":"M. Alifano","year":"2020","journal-title":"Ann Transl Med"},{"issue":"10","key":"pone.0260988.ref028","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells","volume":"208","author":"MB Fuertes","year":"2011","journal-title":"J Exp Med"},{"issue":"10","key":"pone.0260988.ref029","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"MS Diamond","year":"2011","journal-title":"J Exp Med"},{"issue":"17","key":"pone.0260988.ref030","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1073\/pnas.1016569108","article-title":"Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy","volume":"108","author":"J Stagg","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pone.0260988.ref031","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"G Schiavoni","year":"2011","journal-title":"Cancer Res"},{"issue":"3","key":"pone.0260988.ref032","first-page":"1141","article-title":"Upregulation of interleukin\u201117F in colorectal cancer promotes tumor invasion by inducing epithelial\u2011mesenchymal transition","volume":"42","author":"Y Chen","year":"2019","journal-title":"Oncol Rep"},{"issue":"1","key":"pone.0260988.ref033","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"J Zhao","year":"2020","journal-title":"J Exp Med"},{"key":"pone.0260988.ref034","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3389\/fimmu.2020.00718","article-title":"The Emerging Role of the IL-17B\/IL-17RB Pathway in Cancer","volume":"11","author":"J Bastid","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0260988.ref035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12885-017-3122-y","article-title":"Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer","volume":"17","author":"BA Derman","year":"2017","journal-title":"BMC Cancer"},{"issue":"16","key":"pone.0260988.ref036","doi-asserted-by":"crossref","first-page":"27489","DOI":"10.18632\/oncotarget.14225","article-title":"Preoperative pulmonary function correlates with systemic inflammatory response and prognosis in patients with non-small cell lung cancer: results of a single-institution retrospective study","volume":"8","author":"Y Gao","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"pone.0260988.ref037","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41591-020-0873-9","article-title":"IL-8 and cancer prognosis on immunotherapy","volume":"26","author":"Z Bakouny","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"pone.0260988.ref038","article-title":"The IL-8\/IL-8R Axis: A Double Agent in Tumor Immune Resistance","volume":"4","author":"JM David","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"pone.0260988.ref039","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3389\/fimmu.2019.01818","article-title":"The TNF Paradox in Cancer Progression and Immunotherapy","volume":"10","author":"A Montfort","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"pone.0260988.ref040","first-page":"3820","article-title":"TNF-\u03b1 promotes colon cancer cell migration and invasion by upregulating TROP-2","volume":"15","author":"P Zhao","year":"2018","journal-title":"Oncol Lett"},{"key":"pone.0260988.ref041","doi-asserted-by":"crossref","first-page":"3958069","DOI":"10.1155\/2017\/3958069","article-title":"Dual Roles of IL-27 in Cancer Biology and Immunotherapy","volume":"2017","author":"M Fabbi","year":"2017","journal-title":"Mediators Inflamm"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T14:39:58Z","timestamp":1699886398000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260988"}},"subtitle":[],"editor":[{"given":"Pankaj K.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0260988","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]}}}